| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007306347 |
| P356 | DOI | 10.1038/BJC.2015.306 |
| P932 | PMC publication ID | 4651122 |
| P698 | PubMed publication ID | 26325104 |
| P5875 | ResearchGate publication ID | 281520847 |
| P50 | author | Salvatore Lopez | Q43122922 |
| Elena Bonazzoli | Q85217898 | ||
| P2093 | author name string | Alessandro D Santin | |
| Stefania Bellone | |||
| Peter E Schwartz | |||
| Emiliano Cocco | |||
| Elena Ratner | |||
| Dan-Arin Silasi | |||
| Masoud Azodi | |||
| Carlton L Schwab | |||
| Diana P English | |||
| Jonathan D Black | |||
| Federica Predolini | |||
| Francesca Ferrari | |||
| Gary Altwerger | |||
| P2860 | cites work | HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies | Q26822730 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling | Q27851446 | ||
| Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study | Q27851528 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. | Q27853078 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
| HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges | Q28308118 | ||
| Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 | ||
| Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications | Q34223494 | ||
| Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers | Q34497057 | ||
| A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas | Q34694344 | ||
| Two pathogenetic types of endometrial carcinoma | Q34713298 | ||
| T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo | Q34998509 | ||
| Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab | Q35527141 | ||
| Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes | Q36447819 | ||
| Therapeutic targets: MTOR and related pathways | Q36592032 | ||
| Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? | Q36613598 | ||
| Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma | Q36637663 | ||
| Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review | Q37039136 | ||
| Targeting the human EGFR family in esophagogastric cancer | Q37862077 | ||
| HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. | Q39098938 | ||
| Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). | Q39119683 | ||
| Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib | Q39700483 | ||
| Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines | Q39820639 | ||
| The biology of erbB-2/neu/HER-2 and its role in cancer | Q40567924 | ||
| NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer | Q41925146 | ||
| Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease | Q44617061 | ||
| Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma | Q46684059 | ||
| Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome | Q47231231 | ||
| HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. | Q53587822 | ||
| Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 | ||
| Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer | Q68090336 | ||
| The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage | Q72235719 | ||
| Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells | Q74650838 | ||
| Uterine papillary serous carcinoma: what have we learned over the past quarter century? | Q81088714 | ||
| HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients | Q83367544 | ||
| Para-aortic lymphadenectomy in the management of preoperative grade 1 endometrial cancer confined to the uterine corpus | Q84495683 | ||
| P4510 | describes a project that uses | USPC-ARK-1 | Q54991940 |
| USPC-ARK-2 | Q54991963 | ||
| USPC-ARK-20 | Q54991965 | ||
| USPC-ARK-21 | Q54991967 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| cell line | Q21014462 | ||
| overexpression | Q61643320 | ||
| P304 | page(s) | 1020-1026 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. | |
| P478 | volume | 113 |
| Q37644791 | Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells |
| Q37551185 | Effect of Fu-Zheng-Xiao-Liu Granules on Expression of Human Epidermal Growth Factor Receptor 2 (HER-2) and Proliferation and Apoptosis of Breast Cancer Cell Line SKBR-3. |
| Q91906091 | Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient- a case report |
| Q38598081 | Emerging strategies for targeting PI3K in gynecologic cancer |
| Q90698029 | Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors |
| Q89239902 | Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer |
| Q64072797 | Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy |
| Q45848384 | Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials |
| Q38752466 | Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer. |
| Q90987627 | PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers |
| Q92864431 | PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer |
| Q37696147 | Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells |
| Q61447406 | Silencing the Gene Enhances the Sensitivity of Childhood Leukemia Cells to Chemotherapy Drugs by Suppressing the Phosphorylation of Akt |
| Q38680412 | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression |
| Q57169683 | Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late |
| Q55435506 | The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. |
Search more.